LDLRAD1 Inhibitors
LDLRAD1 Inhibitors target specific signaling pathways and cellular processes to diminish the functional activity of LDLRAD1. GW 9662, acting as a PPARγ antagonist, suppresses transcriptional activity of genes involved in lipid metabolism, which could lead to decreased LDLRAD1 expression. The PI3K inhibitor LY 294002 disrupts PI3K/Akt signaling crucial for cell survival and growth, potentially reducing LDLRAD1 expressio. MEK1 inhibitor PD 98059 blocks the MAPK/ERK pathway, which may result in reduced LDLRAD1 expression or activity. Rapamycin, an mTOR inhibitor, suppresses protein synthesis and cell proliferation, which could lead to decreased levels of LDLRAD1. WZB117 hinders glucose uptake by inhibiting GLUT1, thereby limiting glycolysis and indirectly inhibiting LDLRAD1 by curtailing the energy supply necessary for its function, particularly in the context of lipid metabolism.
Chetomin, through inhibition of HIF, may decrease LDLRAD1 activity in pathways where oxygen levels regulate its expression, given HIF's role in metabolism and angiogenesis. SB 203580 targets p38 MAPK signaling, which could reduce LDLRAD1 function in relation to cellular stress responses. U-73122, a PLC inhibitor, can diminish cellular responses to growth factors and hormones, potentially affecting LDLRAD1 activity where signal transduction is crucial. Sunitinib, by impeding RTK signaling involved in cell proliferation and angiogenesis, may indirectly reduce LDLRAD1 activity if it plays a part in these RTK-regulated processes. PF-04929113, an Hsp90 inhibitor, could destabilize LDLRAD1 if it is an Hsp90 client protein, leading to decreased stability and function in lipid metabolism. Exemestane, by reducing estrogen synthesis, could indirectly influence LDLRAD1 activity through altered lipid homeostasis. Lastly, Simvastatin's inhibition of cholesterol synthesis may invoke compensatory changes in lipid metabolism involving LDLRAD1. Together, these inhibitors act on distinct pathways but converge on the common goal of reducing LDLRAD1 activity without directly interacting with the protein itself.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GW 9662 | 22978-25-2 | sc-202641 | 5 mg | $68.00 | 30 | |
A selective PPARγ antagonist, GW 9662 inhibits PPARγ's transcriptional activity. This can lead to a reduction in LDLRAD1 expression since PPARγ has been implicated in lipid metabolism and homeostasis where LDLRAD1 is also involved. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A potent inhibitor of phosphatidylinositol 3-kinase (PI3K), LY 294002 disrupts PI3K/Akt signaling which is crucial for cell survival and growth. Inhibition of this pathway can decrease LDLRAD1 expression as PI3K signaling can affect various proteins involved in lipid metabolism. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A selective inhibitor of MEK1, PD 98059 blocks the MAPK/ERK pathway, which may indirectly reduce the expression or functional activity of LDLRAD1 as this pathway is involved in cell proliferation and differentiation processes that LDLRAD1 may influence. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor, Rapamycin suppresses mTORC1 activity which can inhibit protein synthesis and cell proliferation. Through this mechanism, Rapamycin can diminish LDLRAD1 protein levels as mTOR signaling is a key regulator of cellular metabolism and growth where LDLRAD1 may play a role. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $48.00 $122.00 $432.00 $812.00 | 4 | |
A glucose transporter 1 (GLUT1) inhibitor, WZB117 restricts glucose uptake leading to reduced glycolysis. This can indirectly inhibit LDLRAD1 by limiting the energy supply necessary for the protein's expression and function in cells where LDLRAD1 is involved in lipid metabolism. | ||||||
Chetomin | 1403-36-7 | sc-202535 sc-202535A | 1 mg 5 mg | $182.00 $661.00 | 10 | |
An inhibitor of hypoxia-inducible factor (HIF), Chetomin diminishes HIF's transcriptional activity. Given that HIF can regulate genes involved in metabolism and angiogenesis, this inhibition may lead to decreased LDLRAD1 activity in pathways where oxygen levels regulate its expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor, SB 203580 impedes p38 MAPK signaling which is implicated in stress response and inflammation. Reduction in p38 MAPK activity can lead to diminished LDLRAD1 function in pathways related to cellular stress responses where LDLRAD1 might be relevant. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
A receptor tyrosine kinase (RTK) inhibitor, Sunitinib hampers RTK signaling involved in cell proliferation and angiogenesis. Inhibiting this pathway may indirectly reduce LDLRAD1 activity if it plays a part in the cellular processes regulated by RTKs. | ||||||
PF-04929113 | 908115-27-5 | sc-364576 sc-364576A | 5 mg 50 mg | $495.00 $1980.00 | ||
A heat shock protein 90 (Hsp90) inhibitor, PF-04929113 destabilizes client proteins of Hsp90, which can lead to decreased stability and activity of LDLRAD1 if it is a client protein of Hsp90 involved in lipid metabolism and homeostasis. | ||||||
Exemestane | 107868-30-4 | sc-203045 sc-203045A | 25 mg 100 mg | $131.00 $403.00 | ||
An aromatase inhibitor, Exemestane reduces estrogen synthesis, which can have downstream effects on lipid metabolism. As LDLRAD1 is implicated in lipid metabolism, inhibiting estrogen synthesis could indirectly reduce LDLRAD1 activity through altered lipid homeostasis. | ||||||